ACE-536 is being developed as a treatment of anemia in a global collaboration with Celgene Corporation.
The trial aims to evaluate the tolerability, pharmacodynamics, safety and pharmacokinetics of ACE-536.
Acceleron will receive a $7.5m payment from Celgene for achieving this milestone event.
Acceleron CEO John Knopf said ACE-536 has the potential to make a significant impact on the treatment of anemia, specifically, in diseases such as Myelodysplastic syndromes and beta-thalassemia in which the severe anemia isn’t well managed by currently available therapies.
"ACE-536 is our fourth internally discovered, developed and manufactured drug to enter human clinical trials in the past five years," Knopf said.